Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Monster Beverage Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Monster Beverage Corp trades at $95.94 (market cap $94.79B). The key difference: Monster Beverage Corp is far larger — about 21.1× ACADIA Pharmaceuticals Inc.'s market cap, and Monster Beverage Corp is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | MNST | |
|---|---|---|
Market Cap | $4.49B | $94.79B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $97.64 |
52-Week Low | $20.06 | $58.65 |
Enterprise Value | $3.69B | $93.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Monster Beverage (MNST) trades at $96.92, down 0.7% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $6.3B in 2022 to $8.3B in 2025 and net income reaching $1.91B. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.58 exceeding the $0.527 forecast. Analyst sentiment remains positive with 53% buy ratings, though valuation metrics appear elevated with a P/E of 47.04.
MNST presents growth opportunities through international expansion and product innovation, with overseas sales reaching 45% of revenue. However, the stock faces risks from premium valuation levels and competitive pressures in the energy drink market. The consensus price target of $91.67 suggests potential downside from current levels, while technical indicators show the stock trading near resistance at $98-$100.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
